Blood Vessel News and Research RSS Feed - Blood Vessel News and Research

Blood Vessels are tubes through which the blood circulates in the body. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins.
Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis -- and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required. [More]
Study points to new therapeutic target to interrupt inflammation, bone erosion in rheumatoid arthritis

Study points to new therapeutic target to interrupt inflammation, bone erosion in rheumatoid arthritis

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis -- and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required. [More]
New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema. [More]
White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

A little white pill may help scientists learn why patients with cystic fibrosis have less exercise capacity than their peers, even if their lungs are relatively healthy. [More]
Serelaxin reduces occurrence of in-hospital worsening heart failure

Serelaxin reduces occurrence of in-hospital worsening heart failure

Serelaxin reduces the occurrence of in-hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX-AHF trial. The results were presented for the first time today at ESC Congress by co-principal investigator Professor John R. Teerlink. [More]
New method could help doctors better understand how drug abuse affects the brain

New method could help doctors better understand how drug abuse affects the brain

A new method for measuring and imaging how quickly blood flows in the brain could help doctors and researchers better understand how drug abuse affects the brain, which may aid in improving brain-cancer surgery and tissue engineering, and lead to better treatment options for recovering drug addicts. [More]
Cancer can be changed from terminal to chronic by cutting liver piece by piece

Cancer can be changed from terminal to chronic by cutting liver piece by piece

New surgical methods give hope to patients with cancer that has spread from the intestine to the liver. The disease can be changed from terminal to chronic by cutting the liver piece by piece using keyhole surgery. [More]
Calcium buildup in coronary arteries of chronic kidney disease patients indicates heart disease risk

Calcium buildup in coronary arteries of chronic kidney disease patients indicates heart disease risk

Calcium buildup in the coronary arteries of chronic kidney disease patients may be a strong indicator of heart disease risk, according to a new study in the Journal of the American Society of Nephrology (JASN). [More]
KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. [More]
FGF proteins play broad roles in wound healing

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows. [More]
Study: Brain tumors hijack the brain's existing blood supply during progression

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time. [More]
Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy. [More]
Scientists discover gene that plays vital role in blood vessel formation

Scientists discover gene that plays vital role in blood vessel formation

Scientists from the University of Leeds have discovered a gene that plays a vital role in blood vessel formation, research which adds to our knowledge of how early life develops. [More]
Study reveals stem cell therapy as a new potential avenue of treatment for stroke

Study reveals stem cell therapy as a new potential avenue of treatment for stroke

A stroke therapy using stem cells extracted from patients' bone marrow has shown promising results in the first trial of its kind in humans. [More]
New clinical trial tests use of gold nanoparticles for treating solid tumors in dogs and cats

New clinical trial tests use of gold nanoparticles for treating solid tumors in dogs and cats

When Michael and Sandra Friedlander first came to the Virginia-Maryland College of Veterinary Medicine three years ago with their dog, Grayton, they learned some bad news: Grayton had nasal adenocarcinoma, a form of cancer with a short life expectancy. [More]
Researchers describe how PAI-1 protein behaves in its short life

Researchers describe how PAI-1 protein behaves in its short life

The human body contains a unique protein that has the unusual property of destroying itself after a few hours of existence - it must therefore be continually recreated and is no stable protein. [More]
New supplement covers current knowledge and methods for management of AAICH

New supplement covers current knowledge and methods for management of AAICH

The Journal of Neurosurgery is pleased to announce today's publication of a supplement to the August issue entitled "Race Against the Clock: Overcoming Challenges in the Management of Anticoagulant-Associated Intracerebral Hemorrhage. [More]
UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

UTHealth scientists identify inhibitory switch to prevent peripheral vascular disease

Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Surgeon explains who needs screening for abdominal aortic aneurysms

Surgeon explains who needs screening for abdominal aortic aneurysms

Bulges in body's major blood vessel can cause potentially lethal ruptures, blood clots. An abdominal aortic aneurysm is a potentially life-threatening condition: If the body's major blood vessel ruptures, it can prove deadly. [More]